Contraindicated Medication Use in Dialysis Patients Undergoing Percutaneous Coronary Intervention.

The article focuses on a study which examined the administration of contraindicated drugs enoxaparin and eptifibatide among dialysis patients who are undergoing percutaneous coronary intervention (PCI). The study included 22,778 dialysis patients who underwent PCI between January 1, 2004 and August 31, 2008 in the U.S. Study population was randomized to either receive enoxaparin, eptifibatide or both. Study authors found that patients who received contraindicated antithrombotics had higher risks of in-hospital bleeding and mortality.